Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin

PHASE3CompletedINTERVENTIONAL
Enrollment

276

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions
Dyslipidemia
Interventions
DRUG

Niacin extended-release (NER)

Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg

DRUG

Niacin extended-release (NER) placebo

Tablets administered once daily for 6 weeks

DRUG

Aspirin (ASA)

Tablets (325 mg) administered once daily for 6 weeks

DRUG

Aspirin (ASA) placebo

Tablets administered once daily for 6 weeks

Trial Locations (40)

15206

Pittsburgh

16635

Duncansville

19438

Harleysville

27262

High Point

27704

Durham

28144

Salisbury

28677

Statesville

29651

Greer

32127

Daytona Beach

32216

Jacksonville

33023

Hollywood

33026

Pembroke Pines

33126

Miami

33770

Largo

34613

Brooksville

35209

Birmingham

45242

Cincinnati

53051

Menomonee Falls

53209

Milwaukee

60610

Chicago

63141

St Louis

66608

Topeka

67005

Arkansas City

67203

Wichita

67207

Wichita

75006

Carrollton

75251

Dallas

78217

San Antonio

78224

San Antonio

78752

Austin

80212

Denver

83704

Boise

84044

Magna

84094

Sandy City

84107

Murray

89146

Las Vegas

92801

Anaheim

94598

Walnut Creek

97239

Portland

98335

Gig Harbor

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY